295 related articles for article (PubMed ID: 22021967)
1. Human papilloma virus vaccines: Current scenario.
Pandhi D; Sonthalia S
Indian J Sex Transm Dis AIDS; 2011 Jul; 32(2):75-85. PubMed ID: 22021967
[TBL] [Abstract][Full Text] [Related]
2. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
McCormack PL; Joura EA
BioDrugs; 2011 Oct; 25(5):339-43. PubMed ID: 21942919
[TBL] [Abstract][Full Text] [Related]
3. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil®): a review of its use in the prevention of premalignant genital lesions, genital cancer and genital warts in women.
McCormack PL; Joura EA
Drugs; 2010 Dec; 70(18):2449-74. PubMed ID: 21142263
[TBL] [Abstract][Full Text] [Related]
4. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
[TBL] [Abstract][Full Text] [Related]
5. Genitoanal human papillomavirus infection and associated neoplasias.
Gross G
Curr Probl Dermatol; 2014; 45():98-122. PubMed ID: 24643181
[TBL] [Abstract][Full Text] [Related]
6. The human papillomavirus vaccines.
Ljubojević S
Acta Dermatovenerol Croat; 2006; 14(3):208. PubMed ID: 17010274
[TBL] [Abstract][Full Text] [Related]
7. Prophylactic HPV vaccination: past, present, and future.
Castle PE; Maza M
Epidemiol Infect; 2016 Feb; 144(3):449-68. PubMed ID: 26429676
[TBL] [Abstract][Full Text] [Related]
8. Summary of the National Advisory Committee on Immunization's updated recommendations on human papillomavirus (HPV) vaccines: Nine-valent human papillomavirus (HPV) of minimum intervals between doses in the HPV immunization schedule.
Tunis MC; Deeks SL;
Can Commun Dis Rep; 2016 Jul; 42(7):149-151. PubMed ID: 29770021
[TBL] [Abstract][Full Text] [Related]
9. A novel vaccine for cervical cancer: quadrivalent human papillomavirus (types 6, 11, 16 and 18) recombinant vaccine (Gardasil).
Govan VA
Ther Clin Risk Manag; 2008 Feb; 4(1):65-70. PubMed ID: 18728721
[TBL] [Abstract][Full Text] [Related]
10. Primary prevention of cervical cancer: prophylactic human papillomavirus vaccines.
Mandic A
J BUON; 2012; 17(3):422-7. PubMed ID: 23033276
[TBL] [Abstract][Full Text] [Related]
11. Human Papillomavirus Vaccine Efficacy and Effectiveness against Cancer.
Kamolratanakul S; Pitisuttithum P
Vaccines (Basel); 2021 Nov; 9(12):. PubMed ID: 34960159
[TBL] [Abstract][Full Text] [Related]
12. Vaccines for preventing HPV-related anogenital infection and neoplasia.
Ferris DG
J Am Osteopath Assoc; 2006 Mar; 106(3 Suppl 1):S9-13. PubMed ID: 16729555
[TBL] [Abstract][Full Text] [Related]
13. [The first vaccine against cancer: the human papillomavirus vaccine].
Bősze P
Orv Hetil; 2013 Apr; 154(16):603-18. PubMed ID: 23587540
[TBL] [Abstract][Full Text] [Related]
14. Estimation of the overall burden of cancers, precancerous lesions, and genital warts attributable to 9-valent HPV vaccine types in women and men in Europe.
Hartwig S; St Guily JL; Dominiak-Felden G; Alemany L; de Sanjosé S
Infect Agent Cancer; 2017; 12():19. PubMed ID: 28400857
[TBL] [Abstract][Full Text] [Related]
15. The Use of Both Therapeutic and Prophylactic Vaccines in the Therapy of Papillomavirus Disease.
Garbuglia AR; Lapa D; Sias C; Capobianchi MR; Del Porto P
Front Immunol; 2020; 11():188. PubMed ID: 32133000
[TBL] [Abstract][Full Text] [Related]
16. Quadrivalent human papillomavirus vaccine.
Barr E; Tamms G
Clin Infect Dis; 2007 Sep; 45(5):609-7. PubMed ID: 17682997
[TBL] [Abstract][Full Text] [Related]
17. What is the significance of the HPV epidemic?
Anorlu RI
Can J Urol; 2008 Feb; 15(1):3860-5. PubMed ID: 18304395
[TBL] [Abstract][Full Text] [Related]
18. Epidemiology, clinical manifestations, and recent advances in vaccination against human papillomavirus.
Broomall EM; Reynolds SM; Jacobson RM
Postgrad Med; 2010 Mar; 122(2):121-9. PubMed ID: 20203463
[TBL] [Abstract][Full Text] [Related]
19. Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
Westra TA; Stirbu-Wagner I; Dorsman S; Tutuhatunewa ED; de Vrij EL; Nijman HW; Daemen T; Wilschut JC; Postma MJ
BMC Infect Dis; 2013 Feb; 13():75. PubMed ID: 23390964
[TBL] [Abstract][Full Text] [Related]
20. Global burden of human papillomavirus and related diseases.
Forman D; de Martel C; Lacey CJ; Soerjomataram I; Lortet-Tieulent J; Bruni L; Vignat J; Ferlay J; Bray F; Plummer M; Franceschi S
Vaccine; 2012 Nov; 30 Suppl 5():F12-23. PubMed ID: 23199955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
